Altavant acquires Onspira Therapeutics

Altavant Sciences has entered into a definitive agreement to acquire USA-based Onspira Therapeutics, a private drug development company similarly focused on therapeutics for rare pulmonary diseases.

This acquisition expands Altavant's pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the US Food and Drug Administration. OSP-101 is in pre-clinical development for the treatment of bronchiolitis obliterans syndrome (BOS), the leading non-infectious complication following lung transplantation and a major cause of death in these patients.

Altavant became a wholly-owned subsidiary of Sumitovant Biopharma, a wholly-owned subsidiary of Sumitomo Dainippon Pharma (TYO: 4506) in December 2019 through a $3 billion strategic alliance between Sumitomo Dainippon Pharma and Roivant Sciences.